Rous S N
J Urol. 1978 Aug;120(2):196-7. doi: 10.1016/s0022-5347(17)57104-9.
Fifty-one women with acute urinary tract infections have been treated with cinoxacin, a new synthetic compound that is similar chemically and in antimicrobial activity to nalidixic acid. Urine cultures were made before treatment was started, midway through the 7 to 10-day course of therapy, 1 week after therapy and 4 to 6 weeks after therapy, if possible. Pre-treatment , mid-therapy and post-therapy evaluations of renal and liver function along with a complete blood count were done. All patients were believed to have lower urinary tract infections. Urine cultures in 48 of the 51 patients (94 per cent) became sterile during therapy and 47 patients (92 per cent) maintained sterile urine 1 week after therapy. Of those patients undergoing followup cultures 4 to 6 weeks after therapy 72 per cent had sterile urine. No significant hematological, renal, hepatic or gastroenterologic toxicity was noted. Cinoxacin seems to be a safe and useful drug in the treatment of urinary tract infections caused by the common gram-negative organisms and there does not seem to be any difference in efficacy between the dosage schedules tested.
51名急性尿路感染女性患者接受了西诺沙星治疗。西诺沙星是一种新型合成化合物，在化学性质和抗菌活性方面与萘啶酸相似。在开始治疗前、7至10天疗程的中途、治疗后1周以及治疗后4至6周（如有可能）进行尿培养。治疗前、治疗中和治疗后对肾功能和肝功能进行评估，并进行全血细胞计数。所有患者均被认为患有下尿路感染。51名患者中有48名（94%）在治疗期间尿培养转阴，47名患者（92%）在治疗后1周尿液保持无菌。在治疗后4至6周接受随访培养的患者中，72%的患者尿液无菌。未观察到明显的血液学、肾脏、肝脏或胃肠毒性。西诺沙星似乎是治疗由常见革兰氏阴性菌引起的尿路感染的一种安全有效的药物，所测试的给药方案之间在疗效上似乎没有差异。
